[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
Purchase Options:
[Skip to Content Landing]
Views 22,395
Citations 0
Editorial
March 28, 2017

The US Preventive Services Task Force Recommendation on Screening for Asymptomatic Celiac DiseaseA Dearth of Evidence

Author Affiliations
  • 1Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota
JAMA. 2017;317(12):1221-1223. doi:10.1001/jama.2017.1105

In this issue of JAMA, the US Preventive Services Task Force (USPSTF) critically examines screening for celiac disease in asymptomatic adults, adolescents, and children.1,2 Celiac disease, one of the most common lifelong disorders in the United States, exhibits a broad spectrum of clinical presentations from subtle or no symptoms to severe malabsorption. The rate of diagnosis of celiac disease has substantially increased over the past 30 years, in part explained by increased awareness but perhaps also by a true increase in the disease. The current prevalence of celiac disease is estimated at 0.71% among US adults and 0.76% among US children.3 However, most celiac disease in the population remains undetected, despite wide availability of accurate serologic tests for the disease. Screening could be one option to detect this condition, especially among populations at high risk of celiac disease but who have not yet developed symptoms. The USPSTF, having set an appropriately high bar, concludes that “the current evidence is insufficient to assess the balance of benefits and harms of screening for celiac disease in asymptomatic persons (I statement)”1 and has recommended that more research is needed in this area.

Although the USPSTF review of this topic may be criticized as premature, the USPSTF has appropriately identified the need for data to provide direction in this fundamental area. The USPSTF applied rigorous methodology to address the effectiveness of screening for celiac disease in an asymptomatic population and found the evidence insufficient.1,2 The conclusion and recommendation of the task force will undoubtedly be disappointing for many clinicians as well as some patients. By design, the task force focuses solely on asymptomatic persons or persons with unrecognized symptoms; screening the general population could potentially detect not only asymptomatic patients but also patients who lack typical symptoms such as weight loss, diarrhea, or malabsorption.46

Celiac disease is now recognized as a heterogeneous disease that largely presents with atypical symptoms, symptoms far removed from the gastrointestinal tract, or no symptoms at all.7,8 Even though these patients are not asymptomatic, they usually lack sufficient clinical features, such as chronic diarrhea and weight loss, that would enable diagnosis. The opportunity to help these patients with undetected celiac disease could be missed without effective case-finding strategies that could include screening. The symptoms of celiac disease can be so insidious that patients may not even realize they have symptoms and not even acknowledge them.5 In general-population screening studies (and indeed in birth cohort studies), most patients with celiac disease lack any excess of symptoms compared with persons without celiac disease.911

Data from the recent National Health and Nutrition Examination Survey suggest that current practice for the detection of celiac disease, which mainly relies on the development of sufficient typical symptoms along with clinical suspicion, is ineffective, missing approximately 70% of affected individuals.3 Patients with atypical or nonspecific symptoms often report a delay in diagnosis of celiac disease that may last for years.12,13 Thus, screening would enable the earlier detection of symptomatic but undetected celiac disease and shorten the duration of symptoms.

The USPSTF review highlights the lack of the data on natural history of silent or subclinical celiac disease and whether these patients progress to symptomatic celiac disease, develop consequent complications, or have spontaneous regression of this condition. In addition to 3 US studies described in this USPSTF review,2 a recent large US population–based study reported that the 5-year cumulative incidence rate of subsequent clinical diagnosis was 11% among individuals with positive celiac serology findings on archived samples.14 Progression to diagnosed celiac disease may not be the only outcome of seropositivity, because spontaneous regression occurs in 20% to 50% of antibody-positive children despite continuing gluten consumption, especially among children with type 1 diabetes mellitus.1518 In a study of 32 children aged 2 to 4 years, 6 (20%) who had positive endomysial antibodies and villous atrophy and who were asymptomatic remained so over 10 years while consuming a gluten-containing diet.4 It is clear that more research is needed to understand the disease course of persons with silent or subclinical celiac disease, including whether there is an abrupt or slow progression toward symptomatic celiac disease, whether the disease in some individuals will remain clinically silent, and what factors determine the clinical course and outcomes among these individuals (Figure). The more crucial issue is whether any of these individuals have decrements in nutrition and health, and subsequent excess mortality, that could be avoided with earlier detection.

Figure.
Potential Clinical Course and Outcomes of Celiac Disease
Potential Clinical Course and Outcomes of Celiac Disease

The USPSTF review also addressed the diagnostic accuracy of tests for celiac disease in asymptomatic patients.2 Overall, the best serologic test for celiac disease is currently tissue transglutaminase (tTG)-IgA, which has a high sensitivity and specificity for untreated celiac disease, especially in high-risk groups. However, the positive predictive value declines when this test is used in settings with low pretest prevalence, such as in the general population. The diagnostic accuracy is important in these low-prevalence settings that include many asymptomatic individuals, so that the use of invasive tests can be minimized. More nuanced approaches to serologic tests, such as combining the highly sensitive tTG-IgA with endomysial antibodies, very high titer tTG-IgA, or serially positive tTG by radioimmunoassay, have a diagnostic accuracy that rivals that of traditional biopsy-based approaches. The recent European Society for Paediatric Gastroenterology Hepatology and Nutrition guidelines for children have a nearly 100% positive predictive value for celiac disease when anti-tTG is 10 times the upper limit of normal or higher, regardless of symptom status.19,20

Although the USPSTF review only discussed 2 non-US studies on the diagnostic accuracy in asymptomatic persons, studies conducted in the general population may be informative. In a study involving 1000 participants, parallel serologic testing and biopsies were undertaken in a random sampling of the general population, demonstrating very high accuracy (approximately 99%) for sequentially positive tTg-IgA and endomysial serology in predicting histologic changes of celiac disease.10 Furthermore, a US study of 3800 attendees at a preventive health fair also showed high positive predictive values (94% for celiac disease) in an adult general population, even though only 60% of people who were positive for tTG-IgA and subsequent endomysial antibodies underwent endoscopic biopsy.21 Neither study showed a correlation between gastrointestinal symptoms and seropositivity. Overall, for settings in which the accuracy of tTG-IgA as a single test is insufficient, these screening strategies can achieve the positive predictive value sufficient for detection of celiac disease in the general population.

Although no studies have directly addressed the benefits and harms of treatment of screen-detected asymptomatic celiac disease compared with treatment initiated after clinical diagnosis, several studies have addressed outcomes of undiagnosed celiac disease in the general population. Some but not all of these studies have demonstrated risk of excess mortality associated with undiagnosed celiac disease (with the diagnosis based on testing archived sera), although that excess risk may take decades to occur.14,2224 One study demonstrated a significant risk of excess mortality only among persons with symptomatic celiac disease but not among asymptomatic patients identified through antibody screening.25 Some excess morbidity, including lymphoma, autoimmune disorders, increased risk of fracture, and obstetric complications, may also occur in undiagnosed celiac disease.14,2628 Furthermore, a recent systematic analysis of celiac disease and obstetric complications indicated that women with diagnosed and treated celiac disease had a 20% decrease of preterm birth compared with those with undiagnosed and untreated celiac disease.28 It is likely that individuals with undiagnosed celiac disease include those with and without symptoms. Most screening studies in the general population of adults or children, or in longitudinal follow-up of birth cohorts, suggest that symptoms are not reliable predictors of celiac disease.6,9,10 More direct evidence to support the screening of the general population is needed because the implications of detection of celiac disease are not negligible.

The task force found no data on the harms of screening for celiac disease in this asymptomatic population. However, some data suggest that treating clinically diagnosed patients with the gluten-free-diet is burdensome for some patients and that the health of patients is not uniformly improved by intervention; in an Italian study involving 98 patients with celiac disease, there was a high rate (28%) of development of the metabolic syndrome a year after diagnosis.29 Perhaps some malabsorption may have some benefits, such as lower body mass index and lower cholesterol levels, in a population exposed to the risks of overnutrition.3032

In summary, current evidence on the effectiveness of screening for celiac disease in asymptomatic populations is scarce or absent and certainly insufficient to recommend for or against screening, as indicated in the USPSTF Recommendation Statement. Recognizing that most celiac disease is undetected and may present with diverse symptoms, it is reasonable that clinicians should have a low threshold for testing for celiac disease, especially in high-risk populations such as those with an affected family member or type 1 diabetes mellitus. In all patients, a family history of celiac disease should be routinely sought, given the influence on disease risk. As the trend toward less invasive testing and more ready access to a gluten-free-diet reduces the burden of diagnosis and treatment, it behooves the medical research community to provide the data to determine who should be screened and treated for celiac disease, and when and how. This will require carefully crafted and ambitious studies to address this question in high-risk groups as well as in the general population, which includes most persons with undetected celiac disease. The increasing adoption of a gluten-free diet by a significant portion of the population may be filling the vacuum left by the uncertainty of current screening and diagnostic approaches.

Back to top
Article Information

Corresponding Author: Joseph A. Murray, MD, Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First St SW, Rochester, MN 55905 (murray.joseph@mayo.edu).

Conflict of Interest Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Murray reported receiving grants from Alvine Pharmaceuticals, Alba Therapeutics, the National Institutes of Health, the Obercotter Foundation, and Broad Medical Research Foundation/CCFA; serving on the advisory board of Celimmune; and serving as a consultant for BioLineRx, GlaxoSmithKline, Genentech, Glenmark Pharmacueticals, Boehringer Ingelheim, ImmunsanT, Institute for Protein Design (PvP Biologics), Takeda, Innovate Biopharma, and Intrexon. Dr Choung reported no disclosures.

References
1.
US Preventive Services Task Force.  Screening for celiac disease: US Preventive Services Task Force recommendation statement.  JAMA. doi:10.1001/jama.2017.1462
2.
Chou  R, Bougatsos  C, Blazina  I, Mackey  K, Grusing  S, Selph  S.  Screening for celiac disease: evidence report and systematic review for the US Preventive Services Task Force.  JAMA. doi:10.1001/jama.2016.10395
3.
Choung  RS, Unalp-Arida  A, Ruhl  CE, Brantner  TL, Everhart  JE, Murray  JA.  Less hidden celiac disease but increased gluten avoidance without a diagnosis in the United States: findings from the National Health and Nutrition Examination Surveys from 2009 to 2014.  Mayo Clin Proc. 2017;92(1):30-38. PubMedArticle
4.
van Koppen  EJ, Schweizer  JJ, Csizmadia  CG,  et al.  Long-term health and quality-of-life consequences of mass screening for childhood celiac disease: a 10-year follow-up study.  Pediatrics. 2009;123(4):e582-e588.PubMedArticle
5.
Kurppa  K, Paavola  A, Collin  P,  et al.  Benefits of a gluten-free diet for asymptomatic patients with serologic markers of celiac disease.  Gastroenterology. 2014;147(3):610-617.PubMedArticle
6.
van der Windt  DA, Jellema  P, Mulder  CJ, Kneepkens  CM, van der Horst  HE.  Diagnostic testing for celiac disease among patients with abdominal symptoms: a systematic review.  JAMA. 2010;303(17):1738-1746.PubMedArticle
7.
Talley  NJ, Valdovinos  M, Petterson  TM, Carpenter  HA, Melton  LJ  III.  Epidemiology of celiac sprue: a community-based study.  Am J Gastroenterol. 1994;89(6):843-846.PubMed
8.
Reilly  NR, Fasano  A, Green  PH.  Presentation of celiac disease.  Gastrointest Endosc Clin N Am. 2012;22(4):613-621.PubMedArticle
9.
Vriezinga  SL, Auricchio  R, Bravi  E,  et al.  Randomized feeding intervention in infants at high risk for celiac disease.  N Engl J Med. 2014;371(14):1304-1315.PubMedArticle
10.
Walker  MM, Murray  JA, Ronkainen  J,  et al.  Detection of celiac disease and lymphocytic enteropathy by parallel serology and histopathology in a population-based study.  Gastroenterology. 2010;139(1):112-119.PubMedArticle
11.
Choung  RS, Rubio-Tapia  A, Lahr  BD,  et al.  Evidence against routine testing of patients with functional gastrointestinal disorders for celiac disease: a population-based study.  Clin Gastroenterol Hepatol. 2015;13(11):1937-1943.PubMedArticle
12.
Vavricka  SR, Vadasz  N, Stotz  M,  et al.  Celiac disease diagnosis still significantly delayed—doctor’s but not patients’ delay responsive for the increased total delay in women.  Dig Liver Dis. 2016;48(10):1148-1154.PubMedArticle
13.
Green  PHR, Stavropoulos  SN, Panagi  SG,  et al.  Characteristics of adult celiac disease in the USA: results of a national survey.  Am J Gastroenterol. 2001;96(1):126-131.PubMedArticle
14.
Choung  RS, Larson  SA, Khaleghi  S,  et al.  Prevalence and morbidity of undiagnosed celiac disease from a community-based study.  Gastroenterology. 2017;152(4):830-839.e5. PubMedArticle
15.
Simell  S, Hoppu  S, Hekkala  A,  et al.  Fate of five celiac disease–associated antibodies during normal diet in genetically at-risk children observed from birth in a natural history study.  Am J Gastroenterol. 2007;102(9):2026-2035.PubMedArticle
16.
Liu  E, Bao  F, Barriga  K,  et al.  Fluctuating transglutaminase autoantibodies are related to histologic features of celiac disease.  Clin Gastroenterol Hepatol. 2003;1(5):356-362.PubMedArticle
17.
Waisbourd-Zinman  O, Hojsak  I, Rosenbach  Y,  et al.  Spontaneous normalization of anti-tissue transglutaminase antibody levels is common in children with type 1 diabetes mellitus.  Dig Dis Sci. 2012;57(5):1314-1320.PubMedArticle
18.
Castellaneta  S, Piccinno  E, Oliva  M,  et al.  High rate of spontaneous normalization of celiac serology in a cohort of 446 children with type 1 diabetes: a prospective study.  Diabetes Care. 2015;38(5):760-766.PubMedArticle
19.
Trovato  CM, Montuori  M, Anania  C,  et al.  Are ESPGHAN “biopsy-sparing” guidelines for celiac disease also suitable for asymptomatic patients?  Am J Gastroenterol. 2015;110(10):1485-1489.PubMedArticle
20.
Tortora  R, Imperatore  N, Capone  P,  et al.  The presence of anti-endomysial antibodies and the level of anti-tissue transglutaminases can be used to diagnose adult coeliac disease without duodenal biopsy.  Aliment Pharmacol Ther. 2014;40(10):1223-1229.PubMedArticle
21.
Katz  KD, Rashtak  S, Lahr  BD,  et al.  Screening for celiac disease in a North American population: sequential serology and gastrointestinal symptoms.  Am J Gastroenterol. 2011;106(7):1333-1339.PubMedArticle
22.
Metzger  MH, Heier  M, Mäki  M,  et al.  Mortality excess in individuals with elevated IgA anti-transglutaminase antibodies: the KORA/MONICA Augsburg cohort study 1989-1998.  Eur J Epidemiol. 2006;21(5):359-365.PubMedArticle
23.
Rubio-Tapia  A, Kyle  RA, Kaplan  EL,  et al.  Increased prevalence and mortality in undiagnosed celiac disease.  Gastroenterology. 2009;137(1):88-93.PubMedArticle
24.
Rubio-Tapia  A, Ludvigsson  JF, Choung  RS,  et al.  Increased mortality among men aged 50 years old or above with elevated IgA anti-transglutaminase antibodies: NHANES III.  BMC Gastroenterol. 2016;16(1):136.PubMedArticle
25.
Corrao  G, Corazza  GR, Bagnardi  V,  et al; Club del Tenue Study Group.  Mortality in patients with coeliac disease and their relatives: a cohort study.  Lancet. 2001;358(9279):356-361.PubMedArticle
26.
Tio  M, Cox  MR, Eslick  GD.  Meta-analysis: coeliac disease and the risk of all-cause mortality, any malignancy and lymphoid malignancy.  Aliment Pharmacol Ther. 2012;35(5):540-551.PubMedArticle
27.
Godfrey  JD, Brantner  TL, Brinjikji  W,  et al.  Morbidity and mortality among older individuals with undiagnosed celiac disease.  Gastroenterology. 2010;139(3):763-769.PubMedArticle
28.
Saccone  G, Berghella  V, Sarno  L,  et al.  Celiac disease and obstetric complications: a systematic review and metaanalysis.  Am J Obstet Gynecol. 2016;214(2):225-234.PubMedArticle
29.
Tortora  R, Capone  P, De Stefano  G,  et al.  Metabolic syndrome in patients with coeliac disease on a gluten-free diet.  Aliment Pharmacol Ther. 2015;41(4):352-359.PubMedArticle
30.
West  J, Logan  RF, Hill  PG,  et al.  Seroprevalence, correlates, and characteristics of undetected coeliac disease in England.  Gut. 2003;52(7):960-965.PubMedArticle
31.
Olén  O, Montgomery  SM, Marcus  C, Ekbom  A, Ludvigsson  JF.  Coeliac disease and body mass index: a study of two Swedish general population-based registers.  Scand J Gastroenterol. 2009;44(10):1198-1206.PubMedArticle
32.
Lewis  NR, Sanders  DS, Logan  RF, Fleming  KM, Hubbard  RB, West  J.  Cholesterol profile in people with newly diagnosed coeliac disease: a comparison with the general population and changes following treatment.  Br J Nutr. 2009;102(4):509-513.PubMedArticle
×